The process of developing new anticancer therapeutics has been considered by some to be expensive, time consuming, bureaucratic, and, to some extent, inefficient. The coronavirus disease 2019 (COVID-19) pandemic has significantly affected clinical oncology studies and underlined the need to embrace and accelerate long-pending and awaited reforms to cancer clinical trial methodology. This article highlights the need for optimal use of technology, reduced paperwork and bureaucracy, speedier trial setup, and greater patient centricity in the design and conduct of future clinical and translational cancer studies around the world.

The main author of the article is Kamal Saini, working for Covance and acting as Lytix' CMO consultant.

CEO in Lytix, Øystein Rekdal, has also contributed to the article.

Read the article online or download the article below.